Adjunctive Host-Directed Therapy With Statins Improves Tuberculosis-Related Outcomes in Mice.
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Journal:The Journal of infectious diseases, Volume: 221, Issue: 7
Tuberculosis (TB) treatment is lengthy and complicated and patients often develop chronic lung disease. Recent attention has focused on host-directed therapies aimed at optimizing immune responses to Mycobacterium tuberculosis (Mtb), as adjunctive treatment given with antitubercular drugs. In addition to their cholesterol-lowering properties, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have broad anti-inflammatory and immunomodulatory activities.